Biodexa Pharmaceuticals annual net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Net Income Growth & History (BDRX)
Biodexa Pharmaceuticals's net income was −£6.4M for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£6.4M | −£655,000 | — |
| 2024 | 2024-12-31 | −£5.7M | £1.4M | — |
| 2023 | 2023-12-31 | −£7.1M | £577,000 | — |
| 2022 | 2022-12-31 | −£7.7M | −£2.2M | — |
| 2021 | 2021-12-31 | −£5.5M | £16.7M | — |
| 2020 | 2020-12-31 | −£22.2M | −£12.1M | — |
| 2019 | 2019-12-31 | −£10.1M | £4.9M | — |
| 2018 | 2018-12-31 | −£15.0M | £1.0M | — |
| 2017 | 2017-12-31 | −£16.1M | £4.1M | — |
| 2016 | 2016-12-31 | −£20.2M | −£10.1M | — |
| 2015 | 2015-12-31 | −£10.1M | — | — |
Biodexa Pharmaceuticals net income trends
Over the last five fiscal years, Biodexa Pharmaceuticals's net income increased from −£22.2M to −£6.4M, a change of £15.8M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...